About MITRO

Company Profile

Management Team

Evolution

News

Radiopharmaceutical CRDMO MITRO Has Raised Nearly 400 Million Yuan to Support the Development of Innovative Drugs!

2024-03-18 00:00

On March 18, 2024, Yantai Dongcheng Pharmaceutical Group Co., Ltd. announced that it agreed to increase the capital and shares of its subsidiary MITRO (Yantai) Biotech Co., Ltd. (hereinafter referred to as "MITRO" or "the company"), which will be led by SDIC investment promotion, SDIC cohesion and Shandong local industrial fund, etc., with a total financing of nearly 400 million yuan.

 

MITRO has a layout in Yantai, Nanjing, Wuxi, Guangzhou and other places. Its main business is to provide CRDMO services for domestic and foreign pharmaceutical companies based on nuclear medicine technology, and is committed to becoming a global leader in nuclear medicine research and development outsourcing.

 

MITRO is fully qualified and well-equipped. Now it has AAALAC certified radioactive laboratory, which can meet the animal welfare standards at home and abroad. It has 26 kinds of nuclide qualification, which can meet the experimental requirements. It is a CRO enterprise with clinical and animal PET/CT, which can realize continuous dynamic and static scanning of large and small animals. MITRO has been deeply engaged in the field of nuclear medicine for many years and has a solid customer base, brand strength and accumulated many years of rich project experience.

 

1

 

In non Nuclear medicine field, as a molecular imaging CRO, MITRO has excellent preclinical molecular labeling capabilities in innovative categories such as small molecules, peptides, antibodies, polysaccharides, cell therapy, etc., has good radioactive tracer production and image analysis capabilities, and has been highly recognized and trusted by world-renowned pharmaceutical companies.

 

In the preclinical stage, MITRO uses tracer and in vivo molecular imaging technology to provide customers with new drug research and development services such as pharmacodynamics research and safety evaluation, covering small molecules, peptides, antibodies, cells, polysaccharides, nucleic acids and other drugs. The business runs through the transformation research of naked (small) mice, rats and monkeys, and has rich experience in molecular labeling.

 

In the clinical stage, MITRO uses tracer technology to help innovative drugs conduct accurate patient screening and diagnosis in clinical trials at home and abroad. The services provided include tracer process development and production, image scanning, and image diagnostic analysis. It is committed to becoming the domestic leader in the subdivision of clinical patient screening using molecular imaging.

 

In Nuclear medicine field, as a one-stop service nuclear drug CRDMO that can provide from early screening compounds to listing registration, MITRO has helped more than 20 nuclear drug products to obtain clinical trial approvals. MITRO can provide one-stop CRO services for nuclear drug sponsors from pharmaceutical studies, non-clinical studies, clinical studies (Phase I-IV), registration, and provide CDMO services such as drug process transfer, process optimization, production and transportation at the clinical stage.

 

Dr. Gilles Tamagnan, global CEO of MITRO MITRO is committed to becoming the world's leading nuclear medicine CRDMO service provider, actively building a preclinical-clinical translation platform and expanding the accompanying diagnostic clinical trial network in China, and building a nuclear medicine clinical trial imaging center abroad to promote the registration of innovative drugs in China and internationally, and to further explore the international market. The company is accelerating the integrated layout of nuclear medicine transformation technology services, actively attracting senior technical personnel at home and abroad, ensuring that the high quality implementation of new drug research is in line with international standards, and helping the development of the nuclear medicine industry.

 

China Investment Promotion said: We are optimistic about the development prospects of nuclear medicine and the application potential of nuclear medicine technology in broader innovative drug research and development. In recent years, nuclear drugs in the technological evolution has entered the era of active targeting, is constantly opening up the application field, the global head pharmaceutical companies have laid out the nuclear drug track, further driving the nuclear drug research and development, production, application of the depth of development. The Medium-and Long-Term Development Plan for Medical Isotopes (2021-2035), released in June 2021, sets out a national-level plan for the development of the nuclear medical and health industry. Technological progress overlay policy support, the domestic nuclear drug industry into the high-speed development track. MITRO has been deeply cultivated in the field of nuclear medicine for many years, has become the domestic nuclear medicine CRDMO advanced enterprises, widely recognized by large pharmaceutical companies at home and abroad, we believe that the high standard of service can help more innovative drug research and development process, to benefit patients around the world.

 

1

 

 

About China Investment Investment

CIC China Merchants is a leading private equity investment management institution in China. It focuses on investment in advanced manufacturing industries, attaches importance to technological innovation, outstanding entrepreneurs and team value, and focuses on investment in intelligent manufacturing, new energy vehicles, life sciences, information and communication technology and other fields. Promote the development of green, digital and service-oriented manufacturing. The accumulated assets under management of the team exceed 100 billion yuan, and the investors include financial institutions, social security funds, state-owned and private capital.

 

About GIC cohesion

SDIC Juli Investment Management Co., Ltd. was established in September 2017. It is a private equity fund management company led by the National Development and Investment Group and led by local state-owned investment companies and social capital. The main shareholders include SDIC Group, Qingdao Guoxin, Shandong Luxin, Henan Investment Group, Hunan Xiangtou, etc. The current fund management scale exceeds 10 billion yuan.

 

About Yantai Yeda Venture Capital

Yantai Yeda Venture Capital Co., Ltd. was established in April 2018. It is a state-owned venture capital institution established by the Yellow Bohai New Area to support the development of high-growth enterprises. It takes the mission of helping the development of industrial innovation clusters and the full-cycle innovation investment business as the pillar., Through marketization, specialization, and branding operations, build a first-class innovation investment platform. Forward-looking, we will focus on strategic emerging industries such as information technology, semiconductors, high-end manufacturing, new energy, life and health, and accurately "irrigate" with funds and resources, raise seedlings and breed, and support the growth of enterprises.

 

      About Yantai Guofeng

        Yantai Guofeng Investment Holding Group Co., Ltd. was established in February 2009 and is a wholly state-owned company. In October 2017, the municipal government officially approved the transformation of Guofeng Group into a state-owned capital investment group, which is managed as a municipal enterprise. The registered capital of the group is 10555.56 million yuan, the total assets are about 360 billion yuan, and the net assets are about 126.4 billion yuan. The credit rating and Fitch BBB international subject rating are stable.

 

      About Chengdu Kechuang Investment

 Chengdu Science and Technology Innovation Investment Group Co., Ltd. is a municipal state-owned equity investment institution led by the Chengdu Municipal Party Committee and Municipal Government. It represents Chengdu to support the development of hard-core science and technology innovation enterprises across the country. By the end of 2023, the group's fund group had reached 125 billion billion yuan, with 464 investment projects and a total of 33 listed investment enterprises. Chengdu Science and Technology Innovation Investment focuses on supporting national high-quality innovative enterprises in the fields of electronic information, military aerospace, nuclear technology application, biomedicine, and technology-based enterprises in the fields of new materials and artificial intelligence that serve the above industries. In the nuclear technology application industry, Chengdu Science and Technology Investment is one of the few local state-owned investment platforms with the whole industry chain investment layout in the country, and has close industrialization cooperation with major enterprises, institutes and leaders in various segments of the industry. Chengdu Kechuang Investment was awarded the top 50 Chinese state-owned investment institutions of Qingke 2023, the top 30 best investment institutions in the western region of 2023, and the main credit rating of AAA.

 

About Shandong Longxin

Shandong Longxin Equity Investment Management Co., Ltd. was established on January 4, 2017. It is a state-owned enterprise in Shandong Province. Shandong State-owned Assets Investment Holding Co., Ltd. is a subsidiary of State-controlled Capital. At present, the business covers venture capital and equity investment, and the fund management team has many years of experience in equity investment. As of the end of June 2023, the total capital assets of state control were 5.8 billion yuan, its funds exceeded 10, the fund management scale exceeded 5 billion yuan, and the total investment was 3 billion yuan.

 

About Biomedical Group

Yantai Biomedical Health Industry Development Group Co., Ltd. was established in 2021 with a registered capital of 1.5 billion yuan. It is a wholly-owned subsidiary of Yantai Guofeng Investment Holding Group Co., Ltd. It undertakes the function of "one platform" of Yantai biomedical industry chain, is responsible for integrating the platform resources of the city's biomedical health and public services, and undertakes the functions of industrial park development and construction, industrial planning, project recruitment, operation management, public services, etc, improve the industrial development service system to help Yantai biomedical industry achieve leapfrog upgrading.